Quantificare v. Canfield Scientific: Federal Circuit Affirms Patent Invalid
Quantificare SA’s US patent covering 3D face and body reconstruction technology was found unpatentable, and the Federal Circuit affirmed that ruling on 25 March 2025 after a 676-day appeal. The affirmance ends Quantificare’s effort to enforce US10070119B2 against imaging rival Canfield Scientific.
Federal Circuit closes the door on Quantificare’s 3D imaging patent
Quantificare SA, a French medical imaging company and holder of US10070119B2, brought this appeal before the Court of Appeals for the Federal Circuit (Case No. 23-1917), filed 19 May 2023. The patent at issue — application number US15/289981 — covers a device and method for reconstructing the face and body in three dimensions, a technology directly relevant to clinical imaging and cosmetic analysis platforms. Canfield Scientific, Inc., a competing imaging system provider, was the respondent.
The Federal Circuit issued its order on 25 March 2025, affirming the lower tribunal’s finding of unpatentability. The single-word operative ruling — ‘AFFIRMED’ — confirms that the appellate panel found no reversible error in the underlying invalidity or cancellation determination. For Quantificare, this means US10070119B2 is cancelled and unenforceable. For Canfield Scientific, the affirmance eliminates any residual risk from this patent and validates the challenge strategy pursued through counsel at Marshall Gerstein & Borun LLP.
The 676-day duration from filing to decision is consistent with contested patentability appeals at the Federal Circuit, which typically involve full briefing cycles and occasional oral argument. The public record does not disclose whether oral argument was held or which specific claim features drove the unpatentability finding. What remains unknown is whether any related Quantificare patents covering overlapping 3D reconstruction methods remain in force, or whether further challenge proceedings are contemplated.
Filing to Unpatentable in 676 days
676 days from appeal filing to Federal Circuit decision — above the median for inter partes appeals
Federal Circuit affirms: what the unpatentability ruling means for both parties
Affirmance means the lower unpatentability finding is final
When the Federal Circuit issues an ‘AFFIRMED’ order in a patentability appeal, it confirms that the appellate panel reviewed the lower tribunal’s record and found no reversible legal error. The underlying determination — that the claims of US10070119B2 are unpatentable — now stands as a final, binding adjudication. No Rule 41 dismissal or procedural termination is involved; this is a merits-based appellate conclusion.
Merits affirmanceQuantificare loses enforcement rights over its 3D reconstruction patent
For Quantificare SA, the affirmance is a definitive adverse outcome. US10070119B2 is cancelled on patentability grounds, stripping the company of any ability to assert the patent against Canfield Scientific or any third party. The ruling also raises questions about the enforceability of closely related patent assets in Quantificare’s portfolio covering similar 3D imaging methods, which competitors and licensees should now assess carefully.
Patent cancelled — unenforceableCanfield Scientific secures freedom to operate in 3D facial imaging
Canfield Scientific’s successful defence at the appellate level confirms its freedom to operate with respect to US10070119B2. With the Federal Circuit having affirmed, Quantificare’s appellate options at this level are exhausted. Any further review would require a petition for certiorari to the US Supreme Court, a route that is rarely granted in patent validity disputes absent a significant circuit split or constitutional question.
FTO confirmedAffirmance raises the bar for 3D imaging patent enforcement
The cancellation of a granted US patent covering 3D face and body reconstruction signals that claim scope in this technology space is under scrutiny. Competitors and product developers in clinical imaging, cosmetic analysis, and digital health should treat this outcome as a prompt to audit similar granted patents in their own portfolios and those of potential asserters. A cancelled patent typically strengthens the prior art landscape against related claims.
Prior art landscape strengthenedFull party and counsel information
| Role | Name | Type | Detail |
|---|---|---|---|
| Plaintiff | Quantificare, SA | Company | Medical imaging technology company — holder of US10070119B2 (3D face/body reconstruction)Search in Eureka ↗ |
| Defendant | Canfield Scientific, Inc. | Company | Canfield Scientific, Inc. — provider of imaging systems for clinical and cosmetic applicationsSearch in Eureka ↗ |
| Plaintiff counsel | Kevin Reiner | Attorney | Counsel for Quantificare, SASearch in Eureka ↗ |
| Plaintiff counsel | Mark D. Giarratana | Attorney | Counsel for Quantificare, SASearch in Eureka ↗ |
| Plaintiff law firm | McCarter & English LLP | Law Firm | Representing Quantificare, SASearch in Eureka ↗ |
| Defendant counsel | Isha S. Shah | Attorney | Counsel for Canfield Scientific, Inc.Search in Eureka ↗ |
| Defendant counsel | Michael R. Weiner | Attorney | Counsel for Canfield Scientific, Inc.Search in Eureka ↗ |
| Defendant counsel | Thomas Lee Duston | Attorney | Counsel for Canfield Scientific, Inc.Search in Eureka ↗ |
| Defendant law firm | Marshall Gerstein & Borun LLP | Law Firm | Representing Canfield Scientific, Inc.Search in Eureka ↗ |
| Presiding judge | Judge N/A | Judge | Court of Appeals for the Federal CircuitSearch in Eureka ↗ |
Official order — verbatim text
The Federal Circuit’s order — ‘THIS CAUSE having been considered, it is ORDERED AND ADJUDGED: AFFIRMED’ — is a summary affirmance, indicating the panel found the unpatentability determination below free of reversible error without requiring extended written analysis. At the Federal Circuit, affirmance under an abuse-of-discretion or substantial-evidence standard is common in PTAB appeals where factual findings on prior art are well-supported. For Quantificare, this forecloses further appellate relief at the circuit level; for Canfield Scientific, it crystallises the cancellation.
US10070119B2 — Device and method to reconstruct face and body in 3D
US10070119B2, filed under application number US15/289981, claims a device and method for reconstructing the human face and body in three dimensions. The patent sits at the intersection of computational imaging, photogrammetry, and clinical aesthetics — a domain with growing relevance in dermatology, plastic surgery planning, and cosmetic product evaluation. The underlying technology involves capturing multi-angle image data and processing it to generate accurate 3D models of facial and body surfaces.
For companies competing in clinical imaging, beauty-tech, or digital health platforms, this patent’s cancellation is strategically significant. Quantificare had positioned 3D reconstruction capability as a core differentiator in the aesthetics imaging market. The loss of this patent weakens the IP perimeter around that technology and may prompt competitors to push into claim territory previously avoided. Patent strategists should treat the cancellation as a signal to reassess claim scope in any pending 3D imaging applications and to monitor Quantificare’s continuation filings for revived claim coverage.
Should you run an FTO analysis against US10070119B2?
Although US10070119B2 has been cancelled following the Federal Circuit’s affirmance, product teams building 3D face and body reconstruction systems should not assume the space is fully clear. Patent families in computational imaging frequently include continuation, divisional, or international equivalents that carry overlapping or broadened claims. Any R&D team commercialising 3D facial scanning, body measurement, or photogrammetric reconstruction technology should verify the full scope of Quantificare’s surviving portfolio before proceeding.
PatSnap Eureka’s FTO Search Agent allows IP and engineering teams to map the full Quantificare patent family, identify live continuation filings, and cross-reference your product’s technical features against claim language in real time. Run a targeted FTO now to confirm whether any related applications — including EP or PCT filings — could present residual risk for your 3D imaging platform before product launch or licensing negotiations.
Run a freedom-to-operate analysis on US10070119B2 to assess your product’s exposure
Run FTO in Eureka →Similar Federal Circuit patentability appeals in 3D imaging and medical imaging
Browse Federal Circuit appeals affirming PTAB unpatentability findings in 3D imaging, photogrammetry, and clinical imaging technology — the same domain as Quantificare v. Canfield Scientific.
What this case signals for the 3D imaging and medical aesthetics IP landscape
The Federal Circuit’s affirmance of unpatentability in Quantificare v. Canfield Scientific has direct implications for IP strategy in clinical and cosmetic imaging.
Cancelled patents expand the FTO window for competing imaging platforms
With US10070119B2 cancelled, companies developing 3D facial and body reconstruction systems face one fewer enforcement risk. However, patent families often contain continuation or divisional applications with overlapping claims. R&D teams should verify whether Quantificare holds related US or EP filings before treating the space as fully clear.
Federal Circuit affirmance signals robust prior art against 3D reconstruction claims
An unpatentability finding affirmed at the Federal Circuit level typically reflects strong prior art or claim construction issues identified during inter partes proceedings. IP teams monitoring this space should review the underlying invalidity grounds — likely obviousness or anticipation — to understand which claim elements proved fatal, informing both prosecution and challenge strategy.
Quantificare v Canfield — key questions answered
The Federal Circuit affirmed the unpatentability of US10070119B2 on 25 March 2025. The order records ‘AFFIRMED’, confirming that the lower tribunal’s cancellation of Quantificare’s 3D face and body reconstruction patent was free of reversible error. The patent is cancelled and unenforceable.
US10070119B2 (application US15/289981) covers a device and method for reconstructing the human face and body in three dimensions — technology used in clinical imaging, cosmetic analysis, and aesthetic medicine platforms. Canfield Scientific, a competitor in the imaging systems market, challenged the patent’s validity, ultimately succeeding at both the initial tribunal level and on appeal to the Federal Circuit.
A basis of termination recorded as ‘Unpatentable’ indicates that the originating proceeding — likely an inter partes review at the PTAB — resulted in cancellation of the patent claims on patentability grounds such as anticipation or obviousness. The Federal Circuit’s affirmance means this cancellation is now final and binding.
After a Federal Circuit affirmance, the losing party’s formal option is to petition the US Supreme Court for a writ of certiorari. However, the Supreme Court grants certiorari in patent validity cases only rarely, typically where a significant circuit split or constitutional issue exists. The public record does not suggest any such extraordinary circumstances here.
The cancellation of US10070119B2 removes one enforcement risk for companies developing 3D face and body reconstruction systems. However, Quantificare may hold related continuation or international patents with overlapping claim scope. Companies in clinical imaging, cosmetic technology, or digital health should conduct an FTO analysis covering the full Quantificare patent family before concluding the space is clear.
PatSnap Eureka searches patents and litigation data to answer instantly.